Researchers develop new method for assessing intravascular platelet activation risk

Researchers from Moscow Institute of Physics and Technology together with their colleagues from National Research Center for Hematology have developed a new method for assessing individual risks of intravascular platelet activation. The latter plays a crucial role in the development of various serious clinical situations such as heart attacks and strokes. The range of circumstances that may be associated with the development of intravascular coagulation is currently actively investigated worldwide. In particular, the onset of intravascular coagulation may be triggered by temporary spikes in blood pressure.

Researchers develop new method for assessing intravascular platelet activation risk
A novel approach for thrombosis risk assessment. Image Credit: Daria Sokol, MIPT Press Office

The suggested approach enables calculating the probability of a hydrodynamic shear-induced activation of platelets — blood cells that initiate formation of the blood clot. It will allow physicians to evaluate the critical level of systolic pressure for individual patients. Above this level, shear-induced platelet activation becomes the leading factor of intravascular coagulation. The study has been published in PLOS ONE.

In clinical practice, risks of blood clotting are usually assessed based on laboratory blood tests such as thromboelastography, APPT, thrombin generation test. Those give a general picture of how stable the liquid state of blood is. The tests enable detecting increased blood clotting tendency and, therefore, higher risks of coagulation. Traditional methods of intravascular coagulation risk assessment are based on in vitro analysis of small blood samples drawn from a vein. Such analysis does not, however, take into account individual characteristics of the patient’s blood circulation such as the intensity of blood flow, cardiac output, etc.

Therefore, until recently intravascular coagulation risk assessments for stress situations accompanied by blood pressure spikes were based on methodologies that could hardly be called evidence-based. Development of the new approach to shear-induced intravascular thrombosis risk assessment is important at least for vessels at the highest risk of coagulation.

Hydrodynamic shear-induced activation of platelets in a vessel starts when cumulative shear stress reaches a critical level. The critical level of cumulative shear stress is a parameter that depends on both the amplitude and the duration of elevated shear stress affecting the platelets in the blood stream. The shear stress characterizes the force between adjacent blood flows moving at different speeds. The problem is, the critical cumulative shear stress value is patient-specific and may vary greatly from patient to patient.

We have studied the way critical cumulative shear stress value may depend on the length of von Willebrand factor molecules. These molecules attach to GP1b receptors on platelets’ surface, acting as a sort of sensors for the hydrodynamic environment the platelets find themselves in. Analyzing conformational dynamics of the VWF molecules on the surface of platelets enabled us to find an analytical expression that links their length to the critical cumulative shear stress value,”

Denis Pushin, Postgraduate student at MIPT

The cumulative shear stress value in a certain artery directly depends on the patient’s arterial blood pressure. The expression discovered in the study makes it possible to determine a given patient’s safe limit of upper arterial blood pressure.

We believe that knowing a patient’s individual systolic blood pressure limit will allow doctors to plan a more effective strategy of personalized antithrombotic treatment,”

Georgy Guria, Professor at MIPT

Source:
Journal reference:

Pushin, D.M., et al. (2020) Platelet activation via dynamic conformational changes of von Willebrand factor under shear. PLOS ONE. https://doi.org/10.1371/journal.pone.0234501.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients